CD4 News and Research

RSS

Microparticle-delivered therapy likely to be the first step toward stopping autoimmune diseases

According to the federal government's National Institute of Neurological Disorders and Stroke, nearly 3 million people worldwide -; with almost a third in the United States -; are living with multiple sclerosis (MS), a disabling neurological disease in which the body's immune system mistakenly attacks nerves feeding information to the central nervous system (the brain and spinal cord). Although rarely fatal, MS can lead to long-term disabilities, and impair movement, muscle control, vision and cognition.

6 Jun 2023

Multiple sclerosis: Immune cell invasion enabled by blood-brain barrier breakdown

Blood-brain barrier breakdown in multiple sclerosis leads to immune cell infiltration into the central nervous system. Antigen presentation at the barrier promotes CD8+ T cell entry, triggering focal breakdown and hindering their invasion.

4 Jun 2023

Scientists investigate how immune system's T cells could fight many coronaviruses at once

Scientists at La Jolla Institute for Immunology (LJI) are investigating how the immune system's T cells react to a wide variety of coronaviruses, ranging from SARS to common cold coronaviruses.

1 Jun 2023

Key insights into immune responses after COVID-19 vaccination in Indigenous people

Researchers evaluated immune responses to COVID-19 BNT162b2 mRNA vaccinations among Indigenous Australian First Nations (FN) individuals by comorbidity and ethnicity.

1 Jun 2023

The immunopathology of post-acute sequelae of SARS-CoV-2 infection: highlighting the knowledge gaps

The immunopathology of post-acute sequelae of SARS-CoV-2 infection (PASC).

31 May 2023

New method may help identify the essential ingredients for making an effective HIV vaccine

Since it was identified in 1984 as the cause of Acquired Immune Deficiency Syndrome (AIDS), the human immunodeficiency virus (HIV) has infected more than 80 million people and been responsible for some 40 million deaths worldwide, according to the World Health Organization (WHO).

30 May 2023

New pan-cancer T cell atlas provides a deeper understanding of complex tumor microenvironment

A new study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, provides a deeper understanding of the vast diversity of T cell states as well as their relationships and roles within the complex tumor microenvironment, bringing a fresh perspective to understanding immunotherapy efficacy in cancer.

29 May 2023

First systematic single-cell analysis of transcriptional variation within the T cell population

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Immune cells play important roles in mediating allograft rejection and tolerance after cardiac transplantation.

25 May 2023

First-in-human nanoparticle HIV vaccine induces broad and publicly targeted helper T cell responses

Researchers from Fred Hutchinson Cancer Center in Seattle, Scripps Research in La Jolla, California, IAVI and other collaborating institutions have characterized robust T-cell responses in volunteers participating in the IAVI G001 Phase 1 clinical trial to test the safety and immune response of a self-assembling nanoparticle HIV vaccine.

25 May 2023

Study shows the potential of TAp63 as a new therapeutic target for rheumatoid arthritis

Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint deterioration. The clinical outcomes of patients with active RA can be improved using anti-rheumatic medications, such as methotrexate (MTX).

22 May 2023

Cross-reactivity between Epstein-Barr virus and protein in multiple sclerosis sheds light on disease development

Research uncovers the association between multiple sclerosis (MS) and antibody reactivity to specific amino acids in CRYAB, along with the increased risk when combined with high EBNA1 responses. The study provides evidence of antibody and T cell cross-reactivity between EBNA1 and CRYAB, highlighting the role of EBV adaptive immune responses in MS development.

21 May 2023

Could personalized neoantigen vaccines prevent the recurrence of pancreatic cancer and increase patient survival?

Researchers conducted a phase I clinical trial of a personalized mRNA neoantigen vaccine.

12 May 2023

Schlafen 12 identified as a novel HIV restriction factor

An international study led by MELIS-UPF researchers from the Infection Biology and Molecular Virology laboratories has identified and characterized Schlafen 12 (SLFN 12) as a novel HIV restriction factor.

10 May 2023

New study finds elevated inflammatory cytokines and lymphocytes linked to rare cases of myocarditis after COVID-19 vaccination

Researchers investigated a cohort of patients who developed myocarditis after SARS-CoV-2 mRNA vaccination.

10 May 2023

UCF researcher develops a new, more precise treatment for acute respiratory viral infections

A University of Central Florida College of Medicine researcher has developed a new, more precise treatment for a major cause of illness around the world each year -; acute respiratory viral infections.

9 May 2023

Ketogenic diet: A metabolic makeover boosting immunity and battling inflammation

A recent study discusses alterations in the human metabolic fingerprint associated with the keto diet.

8 May 2023

People with Long COVID neurological symptoms found to have differences in immune cell profiles and autonomic dysfunction

Twelve people with persistent neurological symptoms after SARS-CoV-2 infection were intensely studied at the National Institutes of Health (NIH) and were found to have differences in their immune cell profiles and autonomic dysfunction.

5 May 2023

NIH researchers gain new insights on rare immune deficiency

In an 11-year study, researchers at the National Institutes of Health have further characterized idiopathic CD4 lymphocytopenia (ICL), a rare immune deficiency that leaves people vulnerable to infectious diseases, autoimmune diseases and cancers.

4 May 2023

HIV status does not affect Tecovirimat treatment outcomes for Mpox virus infection

A retrospective cohort study comparing the clinical presentation and treatment outcomes of people with HIV and those without HIV who were treated with tecovirimat for confirmed mpox virus infection. The study found that HIV status did not seem to affect treatment outcomes.